Cantabio Pharmaceuticals Status
The company acquired Lion Consulting through a reverse merger for $38.8 million, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol CTBO on December 17, 2015.
Developer of biotechnological therapies and intellectual property. The company focuses on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson?s disease, Alzheimer?s disease and other related neurodegenerative diseases. Its strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
Pre-Clinical Trials
Publicly Held
Corporation
Novel technologies developed by #Cantabio to quantifying various redox forms of the DJ-1 protein for early diagnosis of #Parkinsons disease is presented by the company’s CEO, Dr. Toth, at #BiomarkersUK conference in London on April 4, 2022. https://t.co/7ONdtNuagU
Cantabio's drug discovery approach and therapeutic pipeline in #Alzheimers, #Parkinsons and #Diabetes is discussed by Dr. Toth in an interview at Careers in Discovery. https://t.co/HnNBkzJLnr
The company acquired Lion Consulting through a reverse merger for $38.8 million, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol CTBO on December 17, 2015.
Novel technologies developed by #Cantabio to quantifying various redox forms of the DJ-1 protein for early diagnosis of #Parkinsons disease is presented by the company’s CEO, Dr. Toth, at #BiomarkersUK conference in London on April 4, 2022. https://t.co/7ONdtNuagU
Cantabio's drug discovery approach and therapeutic pipeline in #Alzheimers, #Parkinsons and #Diabetes is discussed by Dr. Toth in an interview at Careers in Discovery. https://t.co/HnNBkzJLnr
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review